文献速递精神分裂症与精神病性障碍

芬兰首发精神分裂症患者抗精神病药剂量预防复发的真实世界有效性:全国注册队列研究

Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study.
PubMed 文献 · Lancet Psychiatry · 2022-02-16

该研究基于芬兰全国注册数据,纳入5367例首发精神分裂症住院患者,随访5年或至第五次复发。结果显示,抗精神病药预防再住院的有效性在第二次复发后显著下降,标准剂量在第二次复发前再住院风险最低,而低剂量在第二次复发前与再住院风险升高相关。作者认为预防第二次复发至关重要,首次复发后所有患者应接受足量抗精神病药并加强复发预防。

要点

  • 抗精神病药使用与未使用相比,再住院调整风险比从第二次复发前的0·42升至第二次复发后的0·78。
  • 第二次复发前,标准剂量(0·9至<1·1 defined daily doses per day)再住院风险最低。
  • 第二次复发前,低剂量(<0·6 defined daily doses per day)与标准剂量相比再住院风险更高(aHR 1·54)。

核心结论

  • 抗精神病药预防复发的有效性在第二次复发后显著下降。
  • 预防第二次复发至关重要,首次复发后所有患者应接受足量抗精神病药并加强复发预防。

研究设计与样本

  • 芬兰全国注册的基于注册的队列研究,患者来自全国出院登记,纳入住院诊断为首发精神分裂症且年龄≤45岁的患者。
  • 随访5年病程或至第五次复发,采用个体内分析以消除选择偏倚,并按第二次复发前后分层。
  • 研究人群共5367例,其中男性3444例(64·2%),女性1923例(35·8%),随访开始时平均年龄29·5岁(SD 7·8)。
  • 主要指标为因精神病再住院,定义为出院主要诊断记录为ICD-10编码F20-F29的住院治疗;两次复发间隔至少30天。

主要发现

  • 5367例患者中3058例(57·0%)需要住院。
  • 需要住院的患者中,平均剂量从第一次复发前的1·22 defined daily doses per day(95%CI 1·18-1·26)逐渐增至第五次复发前的1·56 defined daily doses per day(95%CI 1·48-1·64)。
  • 抗精神病药使用与未使用相比,再住院调整风险比从第二次复发前的0·42(95%CI 0·35-0·51)升至第二次复发后的0·78(95%CI 0·62-0·99),p<0·0001。
  • 特定剂量分析呈U形曲线,标准剂量(0·9至<1·1 defined daily doses per day)在第二次复发前再住院风险最低,但第二次复发后并非如此。
  • 第二次复发前,低剂量(<0·6 defined daily doses per day)与标准剂量相比再住院风险更高(aHR 1·54,95%CI 1·06-2·24);第二次复发后无此差异(aHR 1·11,95%CI 0·76-1·62),因第二次复发后所有剂量有效性均降低。

临床怎么用

  • 作者认为预防第二次复发至关重要,首次复发后所有患者应接受足量抗精神病药并加强复发预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antipsychotic doses for relapse prevention in patients with first-episode schizophrenia that have the highest likelihood of success are unknown. We aimed to study the evolution of antipsychotic dose and risk of severe relapse indicated by psychiatric rehospitalisation associated with antipsychotic use and specific dose categories. METHODS: We did a nationwide, register-based cohort study in Finland. Patients were identified from the nationwide Hospital Discharge register, which records all inpatient hospital stays. Patients with first-episode schizophrenia diagnosed as inpatients and who were 45 years or younger were followed-up for 5 years of illness or until a fifth relapse episode. The primary measure was rehospitalisation due to psychosis, which was used as a marker of relapse and defined as inpatient hospital care with an ICD-10 code of F20-F29 diagnosis recorded as the main discharge diagnosis. Time between relapses was required to be at least 30 days to be considered a next relapse. Antipsychotic use was derived from the prescription register. Dose was summed from all concomitant antipsychotics. Antipsychotic effectiveness for preventing rehospitalisation was studied using within-individual analyses to eliminate selection bias, stratifying time to before and after the second relapse. FINDINGS: In total, the study population comprised 5367 patients, of whom 3444 (64·2%) were men and 1923 (35·8%) were women, with a mean age of 29·5 years (SD 7·8) at the start of follow-up. Ethnicity data were not available. 3058 (57·0%) of 5367 patients required hospitalisations. In these patients, the mean dose increased gradually after each new relapse from 1·22 defined daily doses per day (95% CI 1·18-1·26) before the first relapse to 1·56 defined daily doses per day (1·48-1·64) before the fifth relapse. Adjusted hazard ratio (aHR) for rehospitalisation with antipsychotic use versus non-use increased from 0·42 (95% CI 0·35-0·51) before the second relapse to 0·78 (0·62-0·99) after the second relapse (p<0·0001), indicating markedly decreased effectiveness. Analysing specific dose categories revealed a U-shaped curve, showing the lowest rehospitalisation risk during use of the standard dose (0·9 to <1·1 defined daily doses per day) before but not after the second relapse. Low dose (<0·6 defined daily doses per day) was associated with substantially higher rehospitalisation risk (aHR 1·54 [95% CI 1·06-2·24]) versus standard dose before the second relapse, but not after the second relapse (1·11 [0·76-1·62]), owing to reduced effectiveness of all doses after the second relapse. INTERPRETATION: The effectiveness of antipsychotics for relapse prevention decreased substantially after the second relapse. Therefore, prevention of the second relapse is essential, and all patients should receive sufficient antipsychotic doses and enhanced relapse prevention efforts after their first relapse. FUNDING: Academy of Finland and Finnish Ministry of Social Affairs and Health.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Taipale H, Tanskanen A, Correll CU, et al. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study. Lancet Psychiatry. 2022. PMID: 35182475. doi:10.1016/S2215-0366(22)00015-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。